Publications
Detailed Information
Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Su Young | - |
dc.contributor.author | Lee, Seung Hee | - |
dc.contributor.author | Lee, Soo Young | - |
dc.contributor.author | Yang, Seungwon | - |
dc.contributor.author | Noh, Hayeon | - |
dc.contributor.author | Chung, Eun Kyoung | - |
dc.contributor.author | Lee, Jangik I. | - |
dc.date.accessioned | 2017-12-26T01:41:06Z | - |
dc.date.available | 2017-12-26T10:42:42Z | - |
dc.date.issued | 2017-12-20 | - |
dc.identifier.citation | Critical Care, 21(1):319 | ko_KR |
dc.identifier.issn | 1364-8535 | - |
dc.identifier.uri | https://hdl.handle.net/10371/138460 | - |
dc.description.abstract | Background
An optimal therapy for the treatment of pneumonia caused by drug-resistant Acinetobacter baumannii remains unclear. This study aims to compare various antimicrobial strategies and to determine the most effective therapy for pneumonia using a network meta-analysis. Methods Systematic search and quality assessment were performed to select eligible studies reporting one of the following outcomes: all-cause mortality, clinical cure, and microbiological eradication. The primary outcome was all-cause mortality. A network meta-analysis was conducted with a Bayesian approach. Antimicrobial treatments were ranked based on surface under the cumulative ranking curve (SUCRA) value along with estimated median outcome rate and corresponding 95% credible intervals (CrIs). Two treatments were considered significantly different if a posterior probability of superiority (P) was greater than 97.5%. Results Twenty-three studies evaluating 15 antimicrobial treatments were included. Intravenous colistin monotherapy (IV COL) was selected as a common comparator, serving as a bridge for developing the network. Five treatments ranked higher than IV COL (SUCRA, 57.1%; median all-cause mortality 0.45, 95% CrI 0.41–0.48) for reducing all-cause mortality: sulbactam monotherapy (SUL, 100.0%; 0.18, 0.04–0.42), high-dose SUL (HD SUL, 85.7%; 0.31, 0.07–0.71), fosfomycin plus IV COL (FOS + IV COL, 78.6%; 0.34, 0.19–0.54), inhaled COL plus IV COL (IH COL + IV COL, 71.4%; 0.39, 0.32–0.46), and high-dose tigecycline (HD TIG, 71.4%; 0.39, 0.16–0.67). Those five treatments also ranked higher than IV COL (SUCRA, 45.5%) for improving clinical cure (72.7%, 72.7%, 63.6%, 81.8%, and 90.9%, respectively). Among the five treatments, SUL (P = 98.1%) and IH COL + IV COL (P = 99.9%) were significantly superior to IV COL for patient survival and clinical cure, respectively. In terms of microbiological eradication, FOS + IV COL (P = 99.8%) and SUL (P = 98.9%) were significantly superior to IV COL. Conclusions This Bayesian network meta-analysis demonstrated the comparative effectiveness of fifteen antimicrobial treatments for drug-resistant A. baumannii pneumonia in critically ill patients. For survival benefit, SUL appears to be the best treatment followed by HD SUL, FOS + IV COL, IH COL + IV COL, HD TIG, and IV COL therapy, in numerical order. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Pneumonia | ko_KR |
dc.subject | Critically ill patients | ko_KR |
dc.subject | Antimicrobials | ko_KR |
dc.subject | Drug-resistant | ko_KR |
dc.subject | Acinetobacter baumannii | ko_KR |
dc.subject | Network meta-analysis | ko_KR |
dc.title | Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 정수영 | - |
dc.contributor.AlternativeAuthor | 이승희 | - |
dc.contributor.AlternativeAuthor | 이수영 | - |
dc.contributor.AlternativeAuthor | 양승원 | - |
dc.contributor.AlternativeAuthor | 노해연 | - |
dc.contributor.AlternativeAuthor | 정은경 | - |
dc.contributor.AlternativeAuthor | 이장익 | - |
dc.identifier.doi | 10.1186/s13054-017-1916-6 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s). | - |
dc.date.updated | 2017-12-24T04:20:09Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.